Post DOTS, post genomics: The next century of tuberculosis control

Lancet

Volumn 353, Issue 9157, 1999, Pages 1004-1005

  Pym, Alexander S ^a,b   Cole, Stewart T ^a  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DNA VACCINE; TUBERCULOSTATIC AGENT;

HEALTH PROGRAM; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 0033586425     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)02118-2     Document Type: Review

References (17)

1. Dolin P.J., Ravigilione M.C., Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ. 72:1994;213-220.
2. Bayer R., Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet. 345:1995;1545-1548.
3. Results of directly observed short-course chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis. Lancet. 347:1996;358-362.
4. WHO Global Tuberculosis Programme. Global tuberculosis control. WHO report 1998. Geneva: WHO, 1998. WHO/TB/98-237.
5. Murray C.J.L., Salomon J.A.Modeling the impact of global tuberculosis control strategies Proc Natl Acad Sci USA. 95:1998;13881-13886.
6. Kenyon T.A., Mwasekaga M.J., Huebner R.et al. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis. 3:1999;4-11.
7. Zwarenstein M., Schoeman J.H., Vundule C.et al. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet. 352:1998;1340-1343.
8. Pelicic V., Reyrat J.M., Gicquel B. Genetic advances for studying Mycobacterium tuberculosis pathogenicity. Mol Microbiol. 28:1998;413-420.
9. Cole S.T., Brosch R., Parkhill J.et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 393:1998;537-544.
10. Strauss J.E., Falkow S. Microbial pathogenesis: genomics and beyond. Science. 276:1998;707-712.
11. Murray P.J., Aldovini A., Young R.A. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines. Proc Natl Acad Sci USA. 93:1996;934-939.
12. Stover C.K., Bansal G.P., Hanson M.S.et al. Protective immunity elicited by recombinant bacille Calmette-Guérin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med. 178:1993;197-209.
13. Berthet F-X., Lagranderie M., Gounon P.et al. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science. 282:1998;759-762.
14. Tascon R.E., Colston M.J., Ragno S.et al. Vaccination against tuberculosis by DNA injection. Nat Med. 2:1996;888-892.
15. Huygen K., Content J., Denis O.et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med. 2:1996;893-898.
16. Efficacy of single-dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Indian J Lepr. 69:1997;121-129. (reprinted Lepr Rev 1997; 68: 341-49).
17. Jacobs G.G., Johnson J.L., Boom W.H.et al. Tuberculosis vaccines: how close to human testing? Tuber Lung Dis. 78:1997;159-169.